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Abstract
Background: Metabolic syndrome is defined as a cluster of at least three out of five clinical risk factors: abdominal
(visceral) obesity, hypertension, elevated serum triglycerides, low serum high-density lipoprotein (HDL) and insulin
resistance. It is estimated to affect over 20% of the global adult population. Abdominal (visceral) obesity is thought
to be the predominant risk factor for metabolic syndrome and as predictions estimate that 50% of adults will be
classified as obese by 2030 it is likely that metabolic syndrome will be a significant problem for health services and
a drain on health economies.
Evidence shows that regular and consistent exercise reduces abdominal obesity and results in favourable changes
in body composition. It has therefore been suggested that exercise is a medicine in its own right and should be
prescribed as such.
Purpose of this review: This review provides a summary of the current evidence on the pathophysiology of
dysfunctional adipose tissue (adiposopathy). It describes the relationship of adiposopathy to metabolic syndrome
and how exercise may mediate these processes, and evaluates current evidence on the clinical efficacy of exercise
in the management of abdominal obesity. The review also discusses the type and dose of exercise needed for
optimal improvements in health status in relation to the available evidence and considers the difficulty in achieving
adherence to exercise programmes.
Conclusion: There is moderate evidence supporting the use of programmes of exercise to reverse metabolic
syndrome although at present the optimal dose and type of exercise is unknown. The main challenge for health
care professionals is how to motivate individuals to participate and adherence to programmes of exercise used
prophylactically and as a treatment for metabolic syndrome.
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Background
Metabolic syndrome is defined as a cluster of at least
three out of five clinical risk factors: abdominal (visceral)
obesity, hypertension, elevated serum triglycerides, low
serum high-density lipoprotein (HDL) and insulin resist-
ance [1]. The prevalence of metabolic syndrome has
been estimated to be more than 20% of the global adult
population [2, 3]. Of the five clinical risk factors used as
diagnostic criteria for metabolic syndrome, abdominal
obesity appears to be the most predominant [3, 4].
Obesity is defined as a body mass index (BMI) of 30 or
above and has been described as a global pandemic with
approximately 50% of adults worldwide expected to be
obese by 2030 [5]. Abdominal (visceral) obesity, irre-
spective of other fat deposits, is a major risk factor for
systemic inflammation, hyperlipidaemia, insulin resist-
ance and cardiovascular disease (for review, see [6]). The
role of abdominal obesity in the development of insulin
resistance and the metabolic syndrome was described in
1991 [7]. However, abdominal obesity does not always
occur in individuals with an elevated BMI. It was recog-
nised as early as 1981 that normal weight, metabolically
obese, individuals existed due to the presence of exces-
sive visceral fat deposits [8].
Evidence shows that one of the single most important
lifestyle changes for the prevention of many chronic dis-
eases is exercise [9] and as a consequence exercise is
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now recognised as a medical treatment in its own right
[6]. There is growing evidence that regular and consistent
programmes of exercise will reduce abdominal fat deposits
significantly, independent of weight loss [10, 11]. It is
recognised that changes in body composition - particularly
a reduction in abdominal fat deposits - are more import-
ant than reductions in overall body weight, or BMI, in
treating metabolic syndrome. Reductions in abdominal fat
deposits are important because abdominal obesity is a
marker of dysfunctional adipose tissue (adiposopathy)
[12]. Abdominal, or visceral obesity has a central role in
the development of a pro-inflammatory state which we
now know is associated with metabolic syndrome [13]. It
has been suggested that exercise as a medical interven-
tion should be prescribed in terms of its dose, i.e.
mode, intensity, frequency and duration [14]. This was
the basis of the American College of Sports Medicine
Exercise is Medicine® (EIM) initiative [15] and their
guidance on prescribing exercise [16]. As a medical inter-
vention the prescription for exercise should also be specif-
ically based on the individual’s capabilities and needs.
The aim of this review is to (i) summarise current evi-
dence on the pathophysiology of dysfunctional adipose
tissue (adiposopathy), its relationship to metabolic syn-
drome and how exercise may mediate these processes;
and (ii) evaluate current evidence on the clinical efficacy
of exercise in the management of abdominal obesity and
to assess the type and dose of exercise needed for opti-
mal improvements in health status.
Abdominal obesity, adiposopathy and metabolic
dysfunction
To understand the significance of abdominal obesity and
its contribution to metabolic syndrome, it is necessary to
appreciate the link between the diseases associated with
this condition. The accumulation of ectopic fat in tissue
surrounding the viscera is directly related to the devel-
opment of insulin resistance [17]. Insulin resistance is
thought to be the common denominator in the develop-
ment of metabolic syndrome. In addition, evidence sug-
gests that systemic inflammation is an important factor
in its development, through the development of insulin
resistance [18–21]. Visceral fat deposits (abdominal adi-
posity) are associated with the development of adipose
cells that are enlarged and dysfunctional (adiposopathy,
or ‘sick fat’) [21]. Dysfunctional adipose tissue secretes
pro-inflammatory biomarkers including prostaglandins,
C-reactive protein (CRP), and cytokines such as interleu-
kins (e.g. interleukin-6), tumour necrosis factor alpha
(TNF-α), and leptin [22, 23]. With increasing obesity
there is also a corresponding decrease in levels of adipo-
nectin, an antiatherosclerotic adipokine [24]. Inflamma-
tory mediators released by adipose tissue contribute to
the development of type II diabetes, hyperlipidaemia and
cardiovascular disease [25, 26]. If there is a high propor-
tion of fat to muscle this is likely to contribute to this
metabolic dysfunction as an increase in circulation of
free fatty acids requires greater insulin secretion for con-
trol of glucose metabolism. The resulting hyperinsuli-
naemia desensitises insulin-sensitive tissues, which
predisposes individuals to type II diabetes [27]. The de-
crease in adiponectin secretion also inhibits insulin re-
ceptor proteins. Moreover, regular consumption of foods
rich in carbohydrate results in postprandial hypergly-
caemia which causes repetitive acute inflammation
which might contribute to a chronic inflammatory state
[28]. Chronic systemic inflammation increases oxidative
stress and reduces metabolic flexibility, thus perpetuat-
ing metabolic syndrome, leading to a vicious cycle of
disease, depression and further inactivity [29, 30].
Adipose tissue hypoxia also occurs in the obese state
although the mechanisms for this are not fully under-
stood [19]. It has been suggested that deficient angio-
genesis causes decreased blood flow due to reduction in
capillary density and excessive growth of adipose tissue.
This may also be exacerbated by obstructive sleep ap-
noea which is common in obese individuals, and results
in a reduction of oxygen to the tissues [31]. Adipose
tissue, hypoxia is associated with an increased expres-
sion of inflammatory genes and decreased expression of
adiponectin, resulting in local and systemic inflamma-
tion [19, 32, 33]. The response to adipose tissue hyp-
oxia includes insulin sensitivity and glucose intolerance
as adiponectin is associated with normal glucose and
lipid metabolism. Leptin expression has also been
shown to increase in obesity and the likely explanation
for this is adipose tissue hypoxia [34]. This is important
as leptin expression modulates insulin resistance [35].
Furthermore, ghrelin regulation in obese individuals is
affected and serum ghrelin suppression in response to
stomach fullness is impaired which results in a failure
to suppress the continued desire to eat, thus com-
pounding the problem [35].
Hypothlamic-pituitary-adrenal (HPA) axis hyperactiv-
ity is evident in abdominal obesity and is also associ-
ated with insulin resistance due to an increase in
cortisol levels [36]. Cortisol, secreted by the adrenal
glands, is involved in glucogenesis which increases
blood sugar as a response to stress. Epidemiological
data provide evidence for a significant positive associ-
ation between increased cortisol levels and the risk of
developing type II diabetes and atherosclerosis due to a
failure to suppress inflammation [37]. Also, the secre-
tion of low grade inflammatory mediators by adipose
tissues may act as an additional chronic stimulus to the
activation of the HPA axis which in turn results in in-
creased levels of cortisol secretion, resulting in a posi-
tive feedback loop [38].
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It is important to note that not all obese patients de-
velop metabolic syndrome and there exists a cohort of
metabolically ‘healthy’ individuals who are obese [39]. At
present, there is no explanation for this and it is not
known whether these metabolically healthy obese indi-
viduals will eventually develop metabolic syndrome and
are simply experiencing a delayed-onset of disease [24].
Interestingly, there are also normal weight individuals
who are regarded as ‘metabolically obese’ due to the
storage of ectopic fat around the viscera whilst maintain-
ing a normal BMI [40, 41].
When BMI is used as a measure of obesity only a
modest association with cardiovascular risk factors is
found [18]. However, when abdominal obesity measure-
ments, such as waist circumference or waist:hip ratio are
included as a measure of abdominal adiposity a strong
association with cardiovascular and metabolic syndrome
risk factors is found [42–45].
Metabolic dysfunction and exercise
Abdominal adiposity is a reversible condition and its re-
duction can have excellent effects in diminishing cardio-
vascular and metabolic syndrome risk. Evidence from a
study by Brooks, et al. demonstrated that increased ab-
dominal obesity was associated with systemic inflamma-
tion as measured by high-sensitivity C-reactive protein
(hsCRP) [18]. Given the direct link between abdominal
obesity and systemic inflammation it is not surprising
that even modest reductions in abdominal adipose tissue
are accompanied by improvements in metabolic function
and reduced cardiovascular risk.
Several studies show a strong association between
obesity and physical inactivity [46–48] and that meta-
bolic syndrome is associated with sedentary lifestyle and
poor cardiorespiratory fitness [49]. Sedentary behaviour
is widely regarded as activity which involves energy ex-
penditure at the level of 1.0–1.5 metabolic equivalent
units (METS),which usually involves time sitting or lying
down and includes office and computer work and
watching television [50]. Edwardson et al. conducted a
meta-analysis that found that individuals who spend
more time in sedentary behaviours have greater odds of
having metabolic syndrome [50]. A prospective study
which examined the relationship between sedentary be-
havior and metabolic syndrome in 930 men found that
men with middle and high sedentary behavior had a
higher risk of developing metabolic syndrome (65% mid-
dle and 76% high level sedentary behaviour respectively),
than men who were active [51]. A longitudinal study ob-
serving 4840 adults found that improvements in cardio-
metabolic factors occurred in overweight and obese
individuals with increased levels of physical activity, al-
though the participants were those participating in a
health screening programme and were therefore
probably of a higher economic status. At follow-up,
there was a statistically significant decrease in non-HDL
concentrations of 5.8% (overweight) and 4.6% (obese)
relative to baseline, and a decrease in low-density lipo-
protein (LDL) cholesterol concentrations of 4.7% (over-
weight) and 6.1% (obese) relative to baseline [52]. Of the
parameters observed, non-HDL cholesterol and plasma
triglycerides were found to have the largest improvement
when physical activity was increased. A study followed
22,383 participants, aged 30–64 years, comparing meta-
bolic syndrome risk with intensity level of leisure-time
exercise and by occupational and commuting activity
[53]. Leisure-time activity was found to be linearly and
inversely associated with a risk of developing metabolic
syndrome and vigorous-intensity activity alone or a com-
bination of both moderate- and vigorous-intensity activity
was associated with a lower risk of metabolic syndrome.
The researchers classified activity levels according to the
MET equivalent: moderate-intensity at 3–6 METs and
vigorous-intensity > 6 METs. The introduction of in-
creased physical activity into a previously inactive lifestyle
might also break the cycle of inflammation-mediated sick-
ness behaviour as described by Nunn, which suppresses
the desire to undertake physical activity [30].
A systematic review and meta-analysis was conducted
by Ostman et al. 2017 to determine whether exercise re-
versed various indices of metabolic syndrome including
body composition, blood cholesterol, fasting blood glu-
cose, fasting insulin, blood pressure and clinical outcome
[54]. A total of 16 studies (800 participants) were in-
cluded in the review and it was found that aerobic train-
ing produced small improvements in fasting blood
glucose, triglycerides and low-density lipoproteins. Com-
bined aerobic and resistance exercise training resulted a
reduction of 13% in triglycerides only. Nevertheless,
combined with improvements in maximal oxygen uptake
and blood pressure, the overall risk profile for patients
was much improved. When the combined exercise
group was compared with the control group the mean
difference of: waist circumference was − 3.80 cm (95%
CI − 5.65, − 1.95, p < 0.0001); systolic blood pressure
was − 3.79 mmHg (95% CI − 6.18, − 1.40, p = 0.002);
and HDL was 0.14 (95% CI 0.04, 0.25, p = 0.009). The
improvements in waist measurement would suggest
that the long-term risks associated with metabolic syn-
drome were reduced. An earlier review to determine
the effectiveness of ‘lifestyle modification programmes’
on improving metabolic risk factors (blood pressure,
triglycerides and waist circumference) in adults with
metabolic syndrome found reductions in these mea-
sures, although such programmes were said to be more
effective if carried out for more than 12 weeks, thus
emphasising the need for long-term lifestyle modifica-
tions [55].
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There are a number of studies which have specifically in-
vestigated the effect of exercise on abdominal obesity, irre-
spective of total body weight and these are summarised in
a comprehensive review by Pedersen and Saltin [56].
Amongst their findings they reported that a cross-
sectional study of overweight males showed that those
with a high level of fitness (as measured by activity and
maximal oxygen uptake) had lower levels of visceral fat
than their unfit counterparts when scanned using mag-
netic resonance imaging [39]. Lee et al. investigated the ef-
fects of exercise without weight loss on total and
abdominal adiposity and skeletal muscle mass and com-
position in previously sedentary, lean men and in obese
men with and without type II diabetes [11]. It was found
that, even in the absence of weight loss, moderate-
intensity exercise was associated with significant reduc-
tions in total and abdominal fat, and there was a reduction
in skeletal muscle lipid content independent of group.
Stewart et al. investigated the effects of exercise on cardio-
vascular and metabolic disease in older adults and found
that reductions in total and abdominal fatness and in-
crease in leanness were strongly associated with reductions
in risk factors for cardiovascular disease and diabetes, in-
cluding those that constitute metabolic syndrome [57].
Lee et al. conducted a longitudinal study of 32,593 adults
who underwent an abdominal computerised tomography
scan as part of health screening and found that the ratio of
visceral-to-subcutaneous fat was independently associated
with all-cause mortality. This suggests that the location of
fat deposits in the abdomen (viscera) is a better indicator
of metabolic risk than total body fat, which is unsurprising
given the positive association between abdominal adiposity
and systemic inflammation [58].
A number of reviews have shown that exercise training
specifically elicits an anti-inflammatory effect, independ-
ent of weight loss [33, 59–62]. Other metabolic benefits
of exercise were reported in a study on patients with
type II diabetes where pedometer-measured exercise was
not only associated with reductions in systemic inflam-
mation, but also reductions in abdominal obesity and
arterial stiffness [63]. One of the mechanisms for the
anti-inflammatory effect of exercise is a reduction in adi-
pose tissue hypoxia resulting from improved capillary
density blood flow. In a review by Golbidi [24] the in-
verse relationship between exercise, body mass index
(BMI), hip-waist ratio, and waist circumference was de-
scribed. The anti-inflammatory effect of exercise was
also explained as being closely related to oxidative stress.
Exercise was shown to improve glucose tolerance, insu-
lin resistance and lipid metabolism and reduce blood
pressure in both healthy individuals and those with
metabolic disease. Large population cohort studies ob-
served relationships between plasma CRP and the level
of exercise that was independent of obesity as measured
by body mass index [62, 64]. The effect of exercise train-
ing on CRP was investigated in a systematic review
which considered a total of 83 studies of different types.
It was found that exercise training led to a greater re-
duction in CRP when accompanied by a decrease in
BMI, but that significant reductions in CRP occurred
without weight loss [65]. Furthermore, a Cochrane re-
view provided evidence that exercise improved general
health even where no weight was lost because it im-
proved plasma lipoprotein profile [66].
Not all studies provide evidence that exercise train-
ing reduces pro-inflammatory biomarkers. Melo et al.
reviewed 11 studies of patients with type II diabetes
and found insufficient evidence to determine whether
aerobic or resistance exercise improved systemic
levels of inflammatory markers [67]. However, an
earlier review by Hayashino et al. found that both
CRP and IL-6 were reduced by exercise training [68].
It is still unclear whether improvements in inflamma-
tory status are independent of weight loss or entirely
dependent upon the changes in body composition
that result from exercise training [61]. Nevertheless,
Eaton and Eaton observed that the percentage of lean
body mass is critical in avoiding the hyperinsulinae-
mia which predisposes individuals to type II diabetes
because a greater insulin secretion is required for any
given glucose load where levels of body fat are dis-
proportionate [27]. This would suggest that strength
training that develops lean tissue is critical in the
treatment, or prevention, of metabolic disease.
Optimal dose of exercise
There are no specific guidelines on exercise prescription
for systemic inflammation although guidance is available
in the form of programmes designed to reduce body fat
and improve general health status. The American College
of Sports Medicine (ACSM) recommends 150–250 min of
moderate-intensity exercise per week as optimal but other
authors have suggested between 30 [69] and 60 [70] mi-
nutes per day would be required. There is a consensus
that performing 3000 steps (~ 30 min of activity) per day
over and above normal activities is sufficient for improve-
ments in health status but perhaps not optimal according
to the ACSM recommendations [71–75]. A systematic re-
view and meta-analysis by Hayashino et al. [68] was con-
ducted to assess the effects of exercise interventions on
inflammatory markers/cytokines and adipokines which
contribute to the development of atherosclerosis, insulin
resistance, and development of late-onset complication in
patients with type II diabetes. They found that exercise
training with a longer duration and frequency was more
effective in reducing systemic inflammation, suggesting
that these effects might be dose-dependent. More recently,
this idea has been challenged and it is now thought that
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shorter-duration, higher intensity interval training (HIIT)
is beneficial [76]. Recent findings suggest that HIIT pro-
grammes are effective in reducing metabolic syndrome
combined with high adherence rates and this is important
because incorporating HIIT programmes into daily life is
less disruptive. Gremeaux, et al. studied the effects of
HIIT training on a sample of 62 overweight or obese
adults who were above the recommended abdominal
obesity threshold. All participants completed 2–3 weekly
sessions of repeated short-duration (15–30 s) interval
training at 80% of their aerobic threshold. It was found
that the prevalence of metabolic syndrome was reduced
by 32.5% at the 9 month follow-up. Importantly, adher-
ence rates to the programme were 97%.
In a study designed to evaluate the effects of different
intensity exercise programmes combined with a healthy
diet in subjects with metabolic syndrome, 75 non-
diabetic subjects were recruited to undertake either a
programme of 10,000 steps per day, a fitness programme
involving activity at > 75% peak VO(2) three times per
week or a 12 week programme of walking 1 h each day
[77]. The metabolic and vascular effects of these three
different regimens were studied and improvements were
observed in various measures including BMI, waist
measurement, glucose metabolism, insulin resistance
and lipid profiles. The more intense exercise regimen at
> 75% peak VO2, combined with a low-sugar diet, was
most effective, which provides further support to the
evidence showing the benefits of HIIT training in com-
bination with dietary advice. A significant observation
was that in 64% of the study participants metabolic syn-
drome was resolved.
Zhang et al. also found that high intensity interval train-
ing was better than continuous moderate aerobic training
in reducing abdominal visceral fat in obese young women
[78]. Similar findings from other studies support the bene-
fit of high-intensity interval training performed in short,
high-intensity bursts, involving as little as 10 min of activ-
ity at a time, and this might promote better adherence in
non-habitual exercisers [79–81]. A further study of 2330
adults found that consistent moderate to vigorous activity
was more important than exercise volume in reducing
CRP levels associated with systemic inflammation [82]. A
systematic review by Cronin et al. found that greater re-
ductions in inflammatory biomarkers occurred in older
healthy inactive participants when higher intensity aerobic
exercise was undertaken [83].
A review by Zdziarski et al. found that largest reduc-
tions in systemic inflammation and improvements in
well-being, depression and sleep was achieved using
multi-modal exercise (aerobic and resistance training) in
individuals with inflammation-related chronic pain [84].
This is important because it is likely that individuals in a
pro-inflammatory state due to abdominal adiposopathy
may also be susceptible to chronic pain conditions.
Dutheil et al. reported that high resistance-moderate en-
durance training was efficient in improving visceral fat
loss in 100 healthy adults [85]. If changes in body com-
position are more important than total body weight loss
then resistance training combined with aerobic exercise
would produce optimal effects in increasing percentage
lean body mass [27].
Promoting adherence to exercise Programmes
One of the major challenges in using programmes of exer-
cise to improve health status is promoting and maintain-
ing adherence in individuals who have often been inactive
for many years and who may be overweight or obese [86].
Ideally, therefore, attempts should be made to include ex-
ercise into normal daily life although attrition rates can
still be as high as 50% [87]. To promote adherence Clauw
and Crofford suggested that additional activity is incorpo-
rated very gradually – as little as 5 min daily [88] although
the programme needs to be tailored to the individual
whilst aiming to deliver optimal effects [84]. As discussed
above, the recent findings that HIIT programmes are ef-
fective in reducing metabolic syndrome combined with
high adherence rates is significant because incorporating
it into daily life is less disruptive. Connelly et al. conducted
a review to assess the effectiveness of technology to pro-
mote physical activity in people with Type 2 diabetes and
found that the use of technology-based interventions,
such as mobile phone applications, texts and email sup-
port, improves compliance [89].
In summary, evidence suggests that optimal abdominal
fat reduction and the development of lean tissue is
achieved by combining high-intensity interval training
and resistance training with an overall general increase
in daily physical activity.
Conclusion
An increasingly sedentary lifestyle, a lack of regular exer-
cise and an increase in obesity have been the main con-
tributors to a rise in the incidence of metabolic
dysfunction, particularly in the developed world. There
is moderate evidence supporting the use of programmes
of exercise to reverse metabolic syndrome although at
present the optimal dose and type of exercise is un-
known. The main challenge for health care professionals
is how to motivate individuals to participate and adher-
ence to programmes of exercise used prophylactically
and as a treatment for metabolic syndrome.
Abbreviations
ACSM: American College of Sports Medicine; BMI: Body mass index; CRP: C-
reactive protein; EIM: Exercise is Medicine; HDL: High density lipoprotein;
HIIT: High Intensity Interval Training; HPA: Hypothlamic-pituitary-adrenal;
hsCRP: High-sensitivity C-reactive protein; LDL: Low density lipoprotein;
METS: Metabolic equivalent units; TNF-α: Tumour necrosis factor alpha;
VO2: Oxygen Uptake
Paley and Johnson BMC Sports Science, Medicine and Rehabilitation  (2018) 10:7 Page 5 of 8
Funding
The production of this review was not funded by any source.
Author contributions
CP was responsible for collating the required information for the review,
drafting the initial review and writing the final report. MJ was responsible for
providing explanation of the physiology, for assisting with the synthesis of
information gathered and the writing of the final draft. Both authors read
and approved the final manuscript.
Competing interests
The authors have no competing interests to declare.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 15 January 2018 Accepted: 26 April 2018
References
1. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et
al. Harmonizing the metabolic syndrome: a joint interim statement of the
international diabetes federation task force on epidemiology and
prevention; National Heart, Lung, and Blood Institute; American Heart
Association; world heart federation; international atherosclerosis society; and
International Association for the Study of obesity. Circulation. 2009;120(16):
1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.
2. Shin J-A, Lee J-H, Lim S-Y, Ha H-S, Kwon H-S, Park Y-M, et al. Metabolic
syndrome as a predictor of type 2 diabetes, and its clinical interpretations
and usefulness. Journal Of Diabetes Investigation. 2013;4(4):334–43.
https://doi.org/10.1111/jdi.12075.
3. Park Y-W, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB.
The metabolic syndrome: prevalence and associated risk factor findings in
the US population from the third National Health and nutrition examination
survey, 1988-1994. Arch Intern Med. 2003;163(4):427–36.
4. Fujita T. Insulin resistance and salt-sensitive hypertension in metabolic
syndrome. Nephrol Dial Transplant. 2007;22(11):3102–7.
5. WHO. Obesity and overweight. In: Factsheet: WHO; 2014. http://www.who.
int/mediacentre/factsheets/fs311/en/. Accessed September 2017.
6. Pedersen BK, Saltin B. Exercise as medicine – evidence for prescribing
exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports.
2015;25:1–72. https://doi.org/10.1111/sms.12581.
7. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care.
1991;14(12):1132–43. https://doi.org/10.2337/diacare.14.12.1132.
8. Ruderman NB, Schneider SH, Berchtold P. The "metabolically-obese,"
normal-weight individual. Am J Clin Nutr. 1981;34(8):1617–21.
9. Cardinal BJ, Park EA, Kim M, Cardinal MK. If exercise is medicine, where is
exercise in medicine? Review of U.S. medical education curricula for
physical activity-related content. J Phys Act Health. 2015;12(9):1336–43.
https://doi.org/10.1123/jpah.2014-0316.
10. Davidson LE, Hudson R, Kilpatrick K, Kuk JL, McMillan K, Janiszewski PM, et
al. Effects of exercise modality on insulin resistance and functional limitation
in older adults: a randomized controlled trial. Arch Intern Med. 2009;169(2):
122–31. https://doi.org/10.1001/archinternmed.2008.558.
11. Lee S, Kuk JL, Davidson LE, Hudson R, Kilpatrick K, Graham TE, et al. Exercise
without weight loss is an effective strategy for obesity reduction in obese
individuals with and without Type 2 diabetes. J Appl Physiol (1985). 2005;
99(3):1220–5.
12. Després J-P, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al.
Abdominal obesity and the metabolic syndrome: contribution to global
cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28(6):1039–49.
https://doi.org/10.1161/ATVBAHA.107.159228.
13. Ritchie SA, Connell JMC. The link between abdominal obesity, metabolic
syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 2007;
17(4):319–26.
14. Swisher AK. Yes, “Exercise is Medicine”….but It Is So Much More.
Cardiopulm Phys Ther J. 2010;21(4):4.
15. ACSM. Exercise is Medicine (EIM). American College of Sports Medicine.
2007. http://www.exerciseismedicine.org/. Accessed 13/10/2017.
16. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et
al. American College of Sports Medicine position stand. Quantity and
quality of exercise for developing and maintaining cardiorespiratory,
musculoskeletal, and neuromotor fitness in apparently healthy adults:
guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43(7):1334–59.
https://doi.org/10.1249/MSS.0b013e318213fefb.
17. Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Postano V, Buzzigoli E, et al. Visceral
fat in hypertension. Influence on Insulin Resistance and β-Cell Function. 2004;
44(2):127–33. https://doi.org/10.1161/01.HYP.0000137982.10191.0a.
18. Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to
abdominal adiposity. Am J Cardiol. 2010;106(1):56–61. https://doi.org/10.
1016/j.amjcard.2010.02.017.
19. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin
resistance. Int J Obes (2005). 2009;33(1):54–66. https://doi.org/10.1038/ijo.
2008.229.
20. Ryan AS, Ge S, Blumenthal JB, Serra MC, Prior SJ, Goldberg AP. Aerobic
exercise and weight loss reduce vascular markers of inflammation and
improve insulin sensitivity in obese women. J Am Geriatr Soc. 2014;62(4):
607–14. https://doi.org/10.1111/jgs.12749.
21. Huth C, Pigeon É, Riou M-È, St-Onge J, Arguin H, Couillard E, et al. Fitness,
adiposopathy, and adiposity are independent predictors of insulin sensitivity
in middle-aged men without diabetes. J Physiol Biochem. 2016;72(3):435–
44. https://doi.org/10.1007/s13105-016-0488-2.
22. Ellulu MS, Khaza'ai H, Rahmat A, Patimah I, Abed Y. Obesity can predict and
promote systemic inflammation in healthy adults. Int J Cardiol. 2016;215:
318–24. https://doi.org/10.1016/j.ijcard.2016.04.089.
23. Das UN. Is obesity an inflammatory condition. Nutrition (Burbank, Los
Angeles County, Calif). 2001;17(11–12):953–66.
24. Golbidi S, Mesdaghinia A, Laher I. Exercise in the metabolic syndrome.
Oxidative Med Cell Longev. 2012;2012:349710. https://doi.org/10.1155/2012/
349710.
25. Guarner V, Rubio-Ruiz ME. Low-grade systemic inflammation connects
aging, metabolic syndrome and cardiovascular disease. Interdiscip Top
Gerontol. 2015;40:99–106. https://doi.org/10.1159/000364934.
26. Marsland AL, McCaffery JM, Muldoon MF, Manuck SB. Systemic
inflammation and the metabolic syndrome among middle-aged
community volunteers. Metab Clin Exp. 2010;59(12):1801–8. https://doi.org/
10.1016/j.metabol.2010.05.015.
27. Eaton SB, Eaton SB. Physical inactivity, obesity, and type 2 diabetes: an
evolutionary perspective. Res Q Exerc Sport. 2017;88(1):1–8. https://doi.org/
10.1080/02701367.2016.1268519.
28. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al.
Inflammatory cytokine concentrations are acutely increased by hyperglycemia
in humans: role of oxidative stress. Circulation. 2002;106(16):2067–72.
29. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From
inflammation to sickness and depression: when the immune system
subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.
30. Nunn AV, Guy GW, Brodie JS, Bell JD. Inflammatory modulation of exercise
salience: using hormesis to return to a healthy lifestyle. Nutr Metab (Lond).
2010;7:87. https://doi.org/10.1186/1743-7075-7-87.
31. Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions
between obesity and obstructive sleep apnea: implications for treatment.
Chest. 2010;137(3):711–9. https://doi.org/10.1378/chest.09-0360.
32. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic
inflammation and adiponectin reduction in adipose tissue of Ob/Ob and
dietary obese mice. Am J Physiol Endocrinol Metab. 2007;293(4):E1118–E28.
33. You T, Arsenis NC, Disanzo BL, Lamonte MJ. Effects of exercise training on
chronic inflammation in obesity : current evidence and potential
mechanisms. Sports Medicine (Auckland, NZ). 2013;43(4):243–56. https://doi.
org/10.1007/s40279-013-0023-3.
34. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity.
Physiol Rev. 2013;93(1):1–21. https://doi.org/10.1152/physrev.00017.2012.
35. Wang T-N, Chang W-T, Chiu Y-W, Lee C-Y, Lin K-D, Cheng YY, et al.
Relationships between changes in leptin and insulin resistance levels in
obese individuals following weight loss. Kaohsiung J Med Sci. 2013;29(8):
436–43. https://doi.org/10.1016/j.kjms.2012.08.041.
36. Prpić-Križevac I, Canecki-Varžić S, Bilić-Ćurčić I. Hyperactivity of the
hypothalamic-pituitary-adrenal axis in patients with type 2 diabetes and
relations with insulin resistance and chronic complications. Wien Klin
Wochenschr. 2012;124(11):403–11. https://doi.org/10.1007/s00508-012-
0191-4.
Paley and Johnson BMC Sports Science, Medicine and Rehabilitation  (2018) 10:7 Page 6 of 8
37. Nijm J, Jonasson L. Inflammation and cortisol response in coronary artery
disease. Ann Med. 2009;41(3):224–33. https://doi.org/10.1080/
07853890802508934.
38. Tsigos C, Kyrou I. Stress, Insulin Resistance, and Type II Diabetes A2 - Fink,
George. Encyclopedia of Stress (Second Edition). New York: Academic Press;
2007. p. 654–9.
39. O'Donovan G, Thomas EL, McCarthy JP, Fitzpatrick J, Durighel G, Mehta S, et
al. Fat distribution in men of different waist girth, fitness level and exercise
habit. Int J Obes (Lond). 2009;33(12):1356–62. https://doi.org/10.1038/ijo.
2009.189.
40. Sharma S, Batsis JA, Coutinho T, Somers VK, Hodge DO, Carter RE, et al.
Normal-weight central obesity and mortality risk in older adults with
coronary artery disease. Mayo Clin Proc. 2016;91(3):343–51. https://doi.org/
10.1016/j.mayocp.2015.12.007.
41. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE,
Sochor O, et al. Normal-weight central obesity: implications for Total and
cardiovascular mortality. Ann Intern Med. 2015;163(11):827–35. https://doi.
org/10.7326/M14-2525.
42. Czernichow S, Kengne AP, Stamatakis E, Hamer M, Batty GD. Body mass
index, waist circumference and waist-hip ratio: which is the better
discriminator of cardiovascular disease mortality risk?: evidence from an
individual-participant meta-analysis of 82 864 participants from nine cohort
studies. Obes Rev. 2011;12(9):680–7. https://doi.org/10.1111/j.1467-789X.
2011.00879.x.
43. Vakil KP, Malhotra S, Sawada S, Campbell SR, Sayfo S, Kamalesh M. Waist
circumference and metabolic syndrome: the risk for silent coronary artery
disease in males. Metab Syndr Relat Disord. 2012;10(3):225–31. https://doi.
org/10.1089/met.2011.0099.
44. Nazare J-A, Smith J, Borel A-L, Aschner P, Barter P, Van Gaal L, et al.
Usefulness of measuring both body mass index and waist circumference for
the estimation of visceral adiposity and related cardiometabolic risk profile
(from the INSPIRE ME IAA study). Am J Cardiol. 2015;115(3):307–15. https://
doi.org/10.1016/j.amjcard.2014.10.039.
45. Kartheuser AH, Leonard DF, Penninckx F, Paterson HM, Brandt D, Remue C,
et al. Waist circumference and waist/hip ratio are better predictive risk
factors for mortality and morbidity after colorectal surgery than body mass
index and body surface area. Ann Surg. 2013;258(5):722–30. https://doi.org/
10.1097/SLA.0b013e3182a6605a.
46. Telford RD. Low physical activity and obesity: causes of chronic disease or
simply predictors? Med Sci Sports Exerc. 2007;39(8):1233–40.
47. Bullock VE, Griffiths P, Sherar LB, Clemes SA. Sitting time and obesity in a
sample of adults from Europe and the USA. Ann Hum Biol. 2017;44(3):230–6.
https://doi.org/10.1080/03014460.2016.1232749.
48. Roda C, Charreire H, Feuillet T, Mackenbach JD, Compernolle S, Glonti K, et
al. Lifestyle correlates of overweight in adults: a hierarchical approach (the
SPOTLIGHT project). Int J Behav Nutr Phys Act. 2016;13(1):114.
49. Lakka TA, Laaksonen DE, Lakka HM, Mannikko N, Niskanen LK, Rauramaa R,
et al. Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic
syndrome. Med Sci Sports Exerc. 2003;35(8):1279–86. https://doi.org/10.
1249/01.mss.0000079076.74931.9a.
50. Edwardson CL, Gorely T, Davies MJ, Gray LJ, Khunti K, Wilmot EG, et al.
Association of sedentary behaviour with metabolic syndrome: a meta-analysis.
Plos One. 2012;7(4):e34916-e. https://doi.org/10.1371/journal.pone.0034916.
51. Greer AE, Sui X, Maslow AL, Greer BK, Blair SN. The effects of sedentary
behavior on metabolic syndrome independent of physical activity and
cardiorespiratory fitness. J Phys Act Health. 2015;12(1):68–73. https://doi.org/
10.1123/jpah.2013-0186.
52. Ritti-Dias RM, Cucato GG, Do Prado WL, RDO C, Santos RD, Bittencourt MS.
Self-initiated changes in physical activity levels improve cardiometabolic
profiles: a longitudinal follow-up study. Nutr Metab Cardiovasc Dis. 2017;
27(1):48–53. https://doi.org/10.1016/j.numecd.2016.10.007.
53. Kuwahara K, Honda T, Nakagawa T, Yamamoto S, Akter S, Hayashi T, et al.
Leisure-time exercise, physical activity during work and commuting, and risk
of metabolic syndrome. Endocrine. 2016;53(3):710–21. https://doi.org/10.
1007/s12020-016-0911-z.
54. Ostman C, Smart NA, Morcos D, Duller A, Ridley W, Jewiss D. The effect of
exercise training on clinical outcomes in patients with the metabolic
syndrome: a systematic review and meta-analysis. Cardiovascular
Diabetology. 2017;16(1):110. https://doi.org/10.1186/s12933-017-0590-y.
55. Lin C-H, Chiang S-L, Tzeng W-C, Chiang L-C. Systematic review of impact of
lifestyle-modification programs on metabolic risks and patient-reported
outcomes in adults with metabolic syndrome. Worldviews Evid-Based Nurs.
2014;11(6):361–8. https://doi.org/10.1111/wvn.12069.
56. Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing
exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports.
2015;25(Suppl 3):1–72. https://doi.org/10.1111/sms.12581.
57. Stewart KJ, Bacher AC, Turner K, Lim JG, Hees PS, Shapiro EP, et al. Exercise
and risk factors associated with metabolic syndrome in older adults. Am J
Prev Med. 28(1):9–18. https://doi.org/10.1016/j.amepre.2004.09.006.
58. Lee SW, Son JY, Kim JM, Hwang S-S, Han JS, Heo NJ. Body fat distribution is
more predictive of all-cause mortality than overall adiposity. Obesity &
Metabolism: Diabetes; 2017. https://doi.org/10.1111/dom.13050.
59. Kasapis C, Thompson PD. The effects of physical activity on serum C-
reactive protein and inflammatory markers: a systematic review. J Am Coll
Cardiol. 2005;45(10):1563–9.
60. Vella CA, Allison MA, Cushman M, Jenny NS, Miles MP, Larsen B, et al.
Physical activity and adiposity-related inflammation: the MESA. Med Sci
Sports Exerc. 2017;49(5):915–21. https://doi.org/10.1249/MSS.
0000000000001179.
61. Wärnberg J, Cunningham K, Romeo J, Marcos A. Physical activity, exercise
and low-grade systemic inflammation. Proc Nutr Soc. 2010;69(3):400–6.
https://doi.org/10.1017/s0029665110001928.
62. Nicklas BJ, You T, Pahor M. Behavioural treatments for chronic systemic
inflammation: effects of dietary weight loss and exercise training. CMAJ:
Canadian Medical Association journal =. Journal De L'association Medicale
Canadienne. 2005;172(9):1199–209.
63. Jennersjö P, Ludvigsson J, Länne T, Nystrom FH, Ernerudh J, Östgren CJ.
Pedometer-determined physical activity is linked to low systemic
inflammation and low arterial stiffness in type 2 diabetes. Diabetic Medicine:
A Journal Of The British Diabetic Association. 2012;29(9):1119–25. https://doi.
org/10.1111/j.1464-5491.2012.03621.x.
64. Bergström G, Behre CJ, Schmidt C. Moderate intensities of leisure-time
physical activity are associated with lower levels of high-sensitivity C-
reactive protein in healthy middle-aged men. Angiology. 2012;63(6):412–5.
https://doi.org/10.1177/0003319711423386.
65. Fedewa MV, Hathaway ED, Ward-Ritacco CL. Effect of exercise training on C
reactive protein: a systematic review and meta-analysis of randomised and
non-randomised controlled trials. British Journal Of Sports Medicine. 2017;
51(8):670–6. https://doi.org/10.1136/bjsports-2016-095999.
66. Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or
obesity. The Cochrane Database Of Systematic Reviews. 2009;4:CD003817.
67. Melo LC, Dativo-Medeiros J, Menezes-Silva CE, Barbosa FT, de Sousa-
Rodrigues CF, Rabelo LA. Physical Exercise on Inflammatory Markers in Type
2 Diabetes Patients: A Systematic Review of Randomized Controlled Trials.
Oxid Med Cell Longev. 2017;2017:8523728. https://doi.org/10.1155/2017/
8523728.
68. Hayashino Y, Jackson JL, Hirata T, Fukumori N, Nakamura F, Fukuhara S, et
al. Effects of exercise on C-reactive protein, inflammatory cytokine and
adipokine in patients with type 2 diabetes: a meta-analysis of randomized
controlled trials. Metab Clin Exp. 2014;63(3):431–40. https://doi.org/10.1016/j.
metabol.2013.08.018.
69. Wareham N, van Sluijs E, Ekelund U. Physical activity and obesity prevention:
a review. Proc Nutr Soc. 2005;64:229–47.
70. Slentz CA, Duscha BD, Johnson JL, Ketchum K, Aiken LB, Samsa GP, et al.
Effects of the amount of exercise on body weight, body composition, and
measures of central obesity: STRRIDE–a randomized controlled study. Arch
Intern Med. 2004;164(1):31–9.
71. Marshall SJ, Levy SS, Tudor-Locke CE, Kolkhorst FW, Wooten KM, Ji M et al.
Translating Physical Activity Recommendations into a Pedometer-Based
Step Goal: 3000 Steps in 30 Minutes. Am J Prev Med. 2009;36(5):410–415.
doi:https://doi.org/10.1016/j.amepre.2009.01.021.
72. Tudor-Locke C, Bassett DR Jr. How many steps/day are enough? Preliminary
pedometer indices for public health. Sports Medicine (Auckland, NZ). 2004;
34(1):1–8.
73. Tudor-Locke C, Bassett DR Jr, Rutherford WJ, Ainsworth BE, Chan CB,
Croteau K, et al. BMI-referenced cut points for pedometer-determined steps
per day in adults. J Phys Act Health. 2008;5(Suppl 1):S126–S39.
74. Tudor-Locke C, Burkett L, Reis JP, Ainsworth BE, Macera CA, Wilson DK. How
many days of pedometer monitoring predict weekly physical activity in
adults? Prev Med. 2005;40(3):293–8.
75. Tudor-Locke C, Craig CL, Brown WJ, Clemes SA, De Cocker K, Giles-Corti B,
et al. How many steps/day are enough? For adults. The International
Paley and Johnson BMC Sports Science, Medicine and Rehabilitation  (2018) 10:7 Page 7 of 8
Journal Of Behavioral Nutrition And Physical Activity. 2011;8:79. https://doi.
org/10.1186/1479-5868-8-79.
76. Gremeaux V, Drigny J, Nigam A, Juneau M, Guilbeault V, Latour E, et al.
Long-term lifestyle intervention with optimized high-intensity interval
training improves body composition, cardiometabolic risk, and exercise
parameters in patients with abdominal obesity. American Journal Of
Physical Medicine & Rehabilitation. 2012;91(11):941–50. https://doi.org/10.
1097/PHM.0b013e3182643ce0.
77. Seligman BGS, Polanczyk CA, Santos ASB, Foppa M, Junges M, Bonzanini L,
et al. Intensive practical lifestyle intervention improves endothelial function
in metabolic syndrome independent of weight loss: a randomized
controlled trial. Metab Clin Exp. 2011;60(12):1736–40. https://doi.org/10.
1016/j.metabol.2011.05.006.
78. Zhang H, Tong TK, Qiu W, Zhang X, Zhou S, Liu Y, et al. Comparable Effects
of High-Intensity Interval Training and Prolonged Continuous Exercise
Training on Abdominal Visceral Fat Reduction in Obese Young Women.
Journal Of Diabetes Research. 2017;2017:5071740. https://doi.org/10.1155/
2017/5071740.
79. Irving BA, Davis CK, Brock DW, Weltman JY, Swift D, Barrett EJ, et al. Effect of
exercise training intensity on abdominal visceral fat and body composition.
Med Sci Sports Exerc. 2008;40(11):1863–72. https://doi.org/10.1249/MSS.
0b013e3181801d40.
80. Giannaki CD, Aphamis G, Sakkis P, Hadjicharalambous M. Eight weeks of a
combination of high intensity interval training and conventional training
reduce visceral adiposity and improve physical fitness: a group-based
intervention. J Sports Med Phys Fitness. 2016;56(4):483–90.
81. Slentz CA, Aiken LB, Houmard JA, Bales CW, Johnson JL, Tanner CJ, et al.
Inactivity, exercise, and visceral fat. STRRIDE: a randomized, controlled study
of exercise intensity and amount. J Appl Physiol (1985). 2005;99(4):1613–8.
82. Loprinzi PD. Frequency of moderate-to-vigorous physical activity (MVPA) is
a greater predictor of systemic inflammation than total weekly volume of
MVPA: implications for physical activity promotion. Physiol Behav. 2015;141:
46–50. https://doi.org/10.1016/j.physbeh.2015.01.002.
83. Cronin O, Keohane DM, Molloy MG, Shanahan F. The effect of exercise
interventions on inflammatory biomarkers in healthy, physically inactive
subjects: a systematic review. QJM: Monthly Journal Of The Association Of
Physicians. 2017; https://doi.org/10.1093/qjmed/hcx091.
84. Zdziarski LA, Wasser JG, Vincent HK. Chronic pain management in the obese
patient: a focused review of key challenges and potential exercise solutions.
J Pain Res. 2015;8:63–77. https://doi.org/10.2147/jpr.s55360.
85. Dutheil F, Lac G, Lesourd B, Chapier R, Walther G, Vinet A, et al. Different
modalities of exercise to reduce visceral fat mass and cardiovascular risk in
metabolic syndrome: the RESOLVE randomized trial. Int J Cardiol. 2013;
168(4):3634–42. https://doi.org/10.1016/j.ijcard.2013.05.012.
86. Loveman E, Frampton GK, Shepherd J, Picot J, Cooper K, Bryant J, et al. The
clinical effectiveness and cost-effectiveness of long-term weight
management schemes for adults: a systematic review. Health Technol
Assess. 2011;15(2):1–182. https://doi.org/10.3310/hta15020.
87. Annesi JJ, Whitaker AC. Weight loss and psychologic gain in obese women-
participants in a supported exercise intervention. The Permanente Journal.
2008;12(3):36–45.
88. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we
know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;
17(4):685–701. doi:https://doi.org/10.1016/S1521-6942(03)00035-4.
89. Connelly J, Kirk A, Masthoff J, MacRury S. The use of technology to promote
physical activity in type 2 diabetes management: a systematic review.
Diabetic Medicine: A Journal Of The British Diabetic Association. 2013;30(12):
1420–32. https://doi.org/10.1111/dme.12289.
Paley and Johnson BMC Sports Science, Medicine and Rehabilitation  (2018) 10:7 Page 8 of 8
